Diagnostics targeting Mycobacterium tuberculosis
In the late 1980s, scientists at the CTR recognised the importance of the polymerase chain reaction (PCR) as a potential diagnostic technique. In order to use this technology, the CTR built the firstever automated PCR machine in Africa. Subsequently, the technology was used to develop an assay to detect resistance-associated genetic mutations to first-line anti-TB drugs. [59] This research introduced clinicians and scientists in Africa to the concept of genetic drug susceptibility testing (gDST). The recent commercialisation of this technique by various diagnostic companies enabled these assays to form an important component of the diagnostic algorithm. [60] The CTR has been involved in testing these assays; for example, in collaboration with the National Health Laboratory Service (NHLS), the CTR evaluated the GenoType MTBDRsl assay, demonstrating excellent sensitivity and specificity for diagnosis of TB and even fluoroquinolone and aminoglycoside resistance, [61, 62] which has now been implemented into routine care. To simplify the interpretation of GenoType assays, a FluoroType assay based on linear-after-theexponential (LATE)-PCR and Lights-On and Lights-Off technology, was developed by the CTR in collaboration with Professor Wangh [63] [20] ─ Recurrent disease by reinfection [17] ─ Association between TB and a polymorphic NF-κB binding site in the IFNγ gene [21] ─ Transmission occurs in community: Adult-to-child [22] and adult-to-adult TB [23] ─ Rate of reinfection higher after successful treatment [24] ─ BCG vaccine induces disease in HIV-infected children [25] ─ Promoter variation in the DC-SIGN-encoding gene CD209 is associated with TB [26] ─ Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary TB patients [27] ─ Evaluation of adapted whole-blood IGRA for the diagnosis of pleural TB [28] ─ EBA and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary TB [29] ─ Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection [30] ─ Clinical relevance of mycobacterial pharmacogenetics [31] ─ Patent: Discovery of new host markers enabling differentiation between active TB and LTBI [32] ─ EBA and pharmacokinetics of PA-824 in smear-positive TB patients [33] ─ Xpert MTB/RIF rapid diagnosis of lymphadenitis [34] ─ Impact of age and sex on mycobacterial immunity in an area of high TB incidence [35] ─ QuantiFERON-TB Gold (In-Tube) assay modification for M. bovis diagnosis in African buffaloes [36] ─ 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations [37] ─ Genotype MTBDRsl shortens time to XDR-TB diagnosis [38] ─ M. tuberculosis population structure determines outcome of genetic DST [39] ─ Potential of novel M. tuberculosis infection phase-dependent antigens in the diagnosis of TB in a high-burden setting [40] ─ Programmatic selection drives XDR-TB evolution [41] ─ M. suricattae [42] ─ TB at the human-livestock-wildlife interface [43] ─ TNF1 controls BCG-triggered TNF production by leukocytes in an area hyperendemic for TB [44] ─ MDR-TB and culture conversion with bedaquiline [45] ─ Diagnostic accuracy of MTBDRsl [46] ─ Associations between human leukocyte antigen class I variants and the M. tuberculosis subtypes causing disease [47] ─ Serum and plasma biomarkers translated into a finger-prick screening test for TB [48] ─ Use of PET-CT as a treatment response monitoring tool [49] ─ Clinical trial: Biomarkers as tools to identify patients eligible for shorter TB treatment duration [50] ─ Novel MAP3K14 mutation in recessive atypical combined immunodeficiency [51] ─ Immune responses to experimental M. bovis infection in the white rhino [52] ─ Detecting micro-heteroresistance [53] ─ Detection of M. bovis in African buffaloes using QuantiFERON-TB Gold tubes and Qiagen cattle type IFNγ ELISA [54] ─ Genetic resistance to M. tuberculosis infection and disease [55] ─ PID in a TB endemic region [56] ─ A sex-stratified GWAS of TB using a multi-ethnic genotyping array [57] ─ Emergence of BDQ resistance [58] RESEARCH and commercialised by Hain Lifescience. This assay has been extensively evaluated by the CTR and showed similar sensitivities as the Xpert MTB/RIF assay for M. tuberculosis detection from sputum samples but with the added advantage of further insight into the molecular mechanisms of resistance for both isoniazid and rifampicin. [63] The implementation of gDST into routine care provided researchers the unique opportunity of determining the utility of these assays on non-sputum samples, including fine-needle aspirate biopsies (FNAB). In collaboration with the NHLS, we developed a protocol for FNAB, using the Xpert MTB/RIF assay, [64] where the sensitivity and specificity for detecting M. tuberculosis in FNAB were 96.7% and 88.9% for adults [34] and 80% and 93.8% for children, respectively. [65] These data contributed to the WHO's recommendation for diagnosing extrapulmonary TB using the Xpert MTB/RIF assay.
Defining the phenotype-genotype association remains critical for the acceptance of gDST. The CTR was the second group globally to evaluate and help develop the Epicenter software (linked to the MGIT 960 instrument), which allowed the determination of minimum inhibitory concentration (MIC) values and pairing these to genotypic data. These studies provided new insight into the genetic basis of resistance to capreomycin, amikacin, ofloxacin, moxifloxacin and ethambutol. [66] [67] [68] [69] Much of these data have contributed to the WHO technical manual for DST of antibiotics used in the treatment of TB. [70] Careful re-evaluation of isoniazid resistance confirmed that inhA promoter region mutations conferred low-level isoniazid resistance and ethionamide cross-resistance. Given that these mutations are easily detected by the MTBDRplus assay, we developed a policy brief requesting this information to be shared with clinicians to ensure standardised multidrug-resistant (MDR) TB treatment could be adjusted accordingly. [71] More recently, we queried the prediction of rifampicin resistance by the Xpert MTB/RIF assay, as MIC testing clearly indicated that not all rpoB mutations confer phenotypic resistance above the critical concentration (1 µg/mL, used to differentiate susceptible from resistant). [72] We have proposed that patients with reduced susceptibility to rifampicin could benefit from either high-dose rifampicin or an alternative rifamycin, namely rifabutin. [73] Clinical trials are now underway to evaluate the efficacy of such regimens but are expected to have great value in certain patients with XDR-TB (http://task.org.za/clinical-trials/).
DST remains technically challenging and it is imperative that alternative molecular-based methods are developed. This is particularly true for pyrazinamide DST, and the CTR has developed a simple workflow to enable detection of pncA mutations in clinical specimens [74] within a 48-hour period. Using this assay, we have shown that over 30% of MDR-TB cases and >90% of extensively drugresistant (XDR)-TB cases have associated PZA resistance routinely RESEARCH undiagnosed [75] which, together with the strong association between ethambutol resistance and MDR-TB, [68] undermines the efficacy of standardised MDR treatment regimens. Ineffective treatment of MDR-TB has allowed the emergence of additional resistance, culminating in XDR-TB, which we termed programmatic selection. [41] These XDR-TB strains are now widespread and largely resistant to available anti-TB drugs and are on the verge of acquiring resistance to new and repurposed drugs. This highlights the need for comprehensive DST prior to treatment initiation to ensure improved outcomes. Through partnerships with the ReSeqTB platform, [76] the CTR continues to contribute by providing whole genome sequence (WGS) data as well as comprehensive phenotypic data. This contribution is essential for the interpretation of WGS data as a diagnostic to guide treatment of DR-TB. [77] Our diagnostic work has provided technical and scientific services to various provincial health departments, the gold mines, some state hospitals and various TB clinics.
Diagnostics are not only about the technology, but also its application in a realworld setting. We conducted a systematic review done as part of a WHO process to directly inform policy on products for TB diagnosis. [78] We also investigated the South African (SA) TB care cascade, which is a tool by policymakers to set goals for strengthening the TB programme. [79] Furthermore, we described innovative approaches for how material typically discarded by laboratories can be used for detailed drug susceptibility testing (thus alleviating the need for additional specimen collection). [80] We recently identified widespread suboptimal performance of the only commercial molecular test for multidrug resistance (MTBDRplus) across dozens of laboratories worldwide and, importantly, demonstrated how this can be corrected by changing the conditions used for DNA amplification. [81] This is now in the process of being incorporated into WHO external quality assessment processes for TB laboratories.
The potential of immune-based point-of-care tests for TB
Despite the amazing progress made in diagnostics targeting the bacillus, there is still much room for improvement, perhaps targeting the host. The use of interferongamma (IFN-γ)-based tests in the diagnosis of TB infection is widely known and hence we evaluated the accuracy of these tests in our high-burden settings. We were amongst the first to show that ex vivo (unprocessed) pleural fluid IFN-γ showed strong potential in the diagnosis of pleural TB. [28] Following the publication of these findings, a highly cited editorial about our work was written, [82] followed by several validation studies in low-and high-burden settings. At least one company is now developing an ex vivo pleural fluid IFN-γ point-of-care test for the disease. [83] We showed that there was high discordance between three known tests for M. tuberculosis infection (tuberculin skin test (TST), QuantiFERON TB Gold and T SPOT. TB) both in HIV-infected and -uninfected adults and children. [84] These studies confirmed the limited value of the new and relatively expensive interferon gamma release assays (IGRAs) over the TST in high-burden countries such as SA. Findings from these studies were replicated in other parts of the world and our articles have been included in meta-analyses that contributed to policy statements on the use of IGRAs. [85, 86] 
Development of a point-of-care fingerprick blood-based test for TB
Following our findings that IGRAs were not necessarily useful in high-burden settings, we were the first to report that the use of three host markers, produced by T cells after stimulation of whole blood with the antigens that are used in IGRAs (ESAT6/CFP10/TB7.7), showed potential as a tool for the diagnosis of active TB (South African Patent: ZA 2009/05156). [30] Similarly, we were one of the first groups conducting large-scale studies on the use of alternative antigens (other than those used in IGRAs) as diagnostic candidates for TB disease. We showed that combinations between different M. tuberculosis infection phase-dependent antigens had potential to be used as diagnostic tools for TB (International Patent: PCT/IB2013/054377; US 14/403,659). In the course of conducting validation studies on these biosignatures in other African countries, however, we noticed that biomarkers detectable in unstimulated blood samples may be more promising than antigen-stimulated biomarkers, besides being more promising as point-of-care diagnostic tests. We identified and validated host protein biosignatures from serum samples which showed strong potential for further development into a point-of-care test for TB (International Patent Application No.s: PCT/ IB2017/052142 and PCT/IB2015/051435) [48] and have successfully developed a pointof-care fingerprick test based on these biomarkers in collaboration with our other African and European partners (www. screen-tb.eu). A clinical trial evaluating the utility of this fingerprick blood-based point-of-care test is currently ongoing in the participating African countries.
The use of positron emission tomography -computerised tomography (PET-CT) and translation of findings from PET-CT findings to more easily implementable tools for monitoring the response to TB treatment
In a ground-breaking study conducted at the CTR, PET-CT imaging technology was used to assess the progress of lesions in TB patients undergoing standard anti-TB therapy (Fig. 3) . The technology was shown to be a useful tool to monitor the response of patients to treatment, through healing of the granulomatous lesions or appearance of Fig. 3 . 18 
F-FDG PET-CT scans tracking the extent and metabolic activity of lung lesions of a cured TB patient during 6 months of standard treatment. Three-dimensional anterior (top) and transverse slices (below, at the level of horizontal blue line). Diagnosis (Dx), month 1 (M1) and month 6 (M6) of treatment.
RESEARCH new ones on the images, with PET-CT images that are consistent with active TB still present in the lungs of several presumed cured patients at the end of treatment. [49] The interpretation of this finding is not yet clear, but may have serious implications and be useful as a monitoring tool for trials. These imaging patterns correlated with the presence of M. tuberculosis mRNA in sputum and broncho-alveolar lavage specimens from these patients at the end of treatment. A randomised controlled trial is currently ongoing in field sites in the Western Cape (SA) and China, aimed at employing PEC-CT imaging and the GeneXpert test results as a TB treatment-shortening tool (www. predict-tb.com). [50] The ultimate aim of the project, which is currently ongoing, is the identification of easily measurable biomarkers that can be used as replacement tools for PET-CT at the point of care.
Clinical trials
TASK Applied Sciences (http://task.org.za), today an extramural clinical research unit with more than 150 employees, had its origins in the CTR. We knew that evaluation of new candidate antibiotics would be important and, to this end, initiated planning for a clinical trial team to be led by Professor Andreas Diacon. At this time, a team led by Koen Andries at Janssen in Beerse, Belgium, discovered a new potential antibiotic active against M. tuberculosis. [87] Preclinical results with TMC207 (bedaquiline) looked promising, but the team hit a roadblock when looking for institutions that could assist with establishing proof-of-concept in actual TB patients. A decades-long dearth of clinical anti-TB drug evaluation had extinguished almost all such research capacity. Moreover, rigorous ethical and methodological standards now applied to testing of new pharmaceuticals. New methods were needed to create evidence of efficacy and safety for a new TB antibiotic. Only registration with strict regulatory authorities would eventually allow the people who needed those drugs to access them. Our team and MRC colleagues in Durban responded and showed that bedaquiline indeed reduced the number of mycobacteria in sputum within the first week of treatment. [29] This work established clinical proof-of-concept for the first new anti-TB treatment in decades. Other projects with new or repurposed antibiotics followed in quick succession. The CTR supported the first formal clinical trials in drug-resistant TB that TASK conducted with bedaquiline in Brooklyn Chest Hospital, Cape Town. These studies were instrumental in obtaining registration for bedaquiline in 2012. [45, 88] The drug has since saved the lives of many patients infected with TB resistant to conventional agents and is now becoming a standard agent in new regimens. Such early bactericidal activity studies for proof-of-concept have become the standard method endorsed by both the US Federal Drug Administration and the European Medicines Agency. TASK, assisted by the University of Cape Town Lung Institute, is now the leading centre for proof-of-concept studies in TB. It is good news that numerous other new or repurposed antibiotics for TB are currently undergoing such testing and are on their way to joining bedaquiline as treatment options. [33, 37, 89, 90] It is very likely that in a few years we will have shorter, safer and better-tolerated treatment regimens available for treatment of TB of various resistance profiles.
Using next-generation sequencing technologies in clinical settings
It is now clear that genetic background influences susceptibility or resistance to TB. We have not yet progressed to being able to use this information for standard TB cases; however, in special cases, genetic tools are already being used. For patients suffering from rare genetic diseases, which can include children who present with BCGosis after vaccination, [25] or multiple episodes of TB, an accurate diagnosis is crucial for treatment and management. The problem is that some rare diseases often present with combinations of symptoms that are unfamiliar to the physicians treating them, making diagnosis challenging. It is estimated that up to 50% of people suffering from a rare genetic disease never receive a diagnosis. [91] Often, these patients have embarked on a 'diagnostic odyssey' that includes consultations with several specialists, a number of invasive interventions and expensive laboratory tests. This very slow process can incur crippling costs for the patient and may not yield the diagnosis they so desperately need, or not in time to benefit the patient.
With the significant reduction in the costs of next-generation DNA sequencing technology, we can now afford to use wholeexome sequencing (WES) in clinical settings to diagnose rare genetic disorders. At the CTR, a multidisciplinary team of researchers and physicians known as the Primary Immunodeficiency Disorders Genetics Research Group (PIDDGEN) has, since 2014, used WES to provide genetic diagnoses for patients with primary immunodeficiency disorders (PIDs). [56] PIDs comprise over 300 different heritable disorders which are caused by inborn errors of the immune system that result in increased susceptibility to infection, autoimmunity, autoinflammation, allergy and tumours. PIDs are challenging to diagnose because of their variable clinical presentations but, in many cases, PIDDGEN has already been able to make a definitive diagnosis only through WES. [51, 92, 93] One such case clearly illustrates the value of WES for diagnosis of PIDs: Patient CE, a young girl from a non-consanguineous marriage, was at two years of age diagnosed with humoral immunodeficiency after presenting with a BCG abscess on the upper leg. CE was placed on intravenous immunoglobulin replacement therapy, but developed BCG meningitis a year later. She subsequently received acute-phase INH, RIF, ETH and dexamethasone treatments and thereafter only INH and RIF. Two years later, the patient presented with acute loss of consciousness and raised intracranial pressure. BCG, genotypically sensitive to all the above prescribed drugs, was cultured from the patient. Immunological workup showed slightly elevated CD4 and B cell levels, with normal T cell proliferations to a range of different mitogens and recall antigens, as well as normal IFN-γ production by T cells. Slightly low CD8 and NK cell levels were observed, with decreased up-regulation of CD69 on NK cells after IL-2 stimulation. T cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs) were clearly visible. Class-switched memory B cells also remained persistently low. The patient's memory T cells were low in relation to the naïve T cells and, interestingly, reduced levels of γ/δ T cells were also observedcells involved in the innate immune reaction against mycobacteria. Exome sequencing of the patient identified a mutation in the NF-κBinducing kinase (NIK) encoding gene, MAP3K14 (homozygous NIKVal345Met). Both parents of this patient were heterozygous carriers of the mutation. Using an overexpression cell model to mimic the effects of the mutations, we showed that the mutation significantly impaired the ability of NIK to phosphorylate IKKα. [51] Subsequent to this finding, we identified the same mutation in another patient presenting with destructive pneumonia and hypogammaglobulinaemia. Both parents were heterozygous carriers of the mutation. This already BCG-vaccinated patient is being monitored closely for any evidence of developing dissemination. A further infant sibling was shown to be negative for the variant.
This case highlights the potential impact of next-generation sequencing (NGS) techniques such as WES on patient care. The integration of WES into clinical settings will enable accurate molecular diagnosis for patients suffering from diseases with unclear phenotypes or atypical presentation. NGS technologies are providing significant opportunities to implement personalised health strategies such as RESEARCH the early detection of disease, improved health maintenance and tailored therapies, particularly for patients with rare genetic diseases.
Tuberculosis in animals
Zoonotic TB was a major component of TB in years gone by, prompting public health efforts such as milk pasteurisation and slaughter of infected livestock to reduce prevalence. TB in livestock has become increasingly recognised as a global problem with serious economic and conservation implications. For this reason, the CTR began investigations into this topic some years ago. In SA, implementation of the CTR Animal TB Group's newly developed bovine tuberculosis (bTB) diagnostic assays such as the QuantiFERON TB-Gold Plus IFN-γ assays and IFN-γ induced protein of 10 kDa (IP-10) assays are now routinely used by conservation organisations such as Hluhluwe iMfolozi Park (HiP) and Kruger National Park (KNP) for the detection of bTB in African buffaloes (Fig. 4 ). [54, [94] [95] [96] For the past 11 years, the Animal TB Group has been successfully involved in HiP's annual African buffalo bTB reduction programme, which has resulted in a significantly reduced bTB prevalence in this species. In KNP, recent discoveries of bTB in African rhinoceros led to South African National Parks (SANParks) developing a TB management policy based on the Animal TB Group's research for these species and various others. [97] [98] [99] Discovery of bovine TB in rhinoceros has prompted the Department of Agriculture, Forestry and Fisheries (DAFF) to place a moratorium on movement of these animals from known infected areas, with negative consequences for conservation. Speciation tests developed in the CTR are now used in the only routine service DAFF-accredited laboratory in SA. This work and other developments have led to far more accurate diagnosis in animals and has overturned assumptions in many interesting cases, for example our finding of M. tuberculosis in a free-ranging African elephant in KNP. [100] The CTR has also described two entirely new species of pathogenic mycobacteria in this process. [101, 102] Research in a wide variety of animals including African wild dogs, African lions, antelope such as the greater kudu ( Fig. 5) , warthogs, hyenas and domestic livestock [103] [104] [105] [106] has drawn the attention of not only the Wildlife Ranching Association of SA, but also that of various private international zoos. We provide ongoing assistance to DAFF, SANParks, the National Zoological Gardens and others, such as the Namibian Wildlife Service, regarding TB in wild and domestic animals. In addition, this research provides a foundation for understanding the risk of zoonotic transmission of M. bovis, as emphasised in the WHO 'Roadmap for Zoonotic TB' . [107] 
Conclusion
Critical initial research findings of the CTR were that the SA TB epidemic was being driven by diverse, highly transmissible strains, harbouring resistance-associated mutations and accumulating further resistance owing to sub-optimal treatment. The epidemic was clearly not under control and therefore we believed that our understanding of disease dynamics was faulty. This view directed the early research agenda towards diagnostics, antibiotic use and resistance, [108] in line with WHO TB research priorities (diagnostics, drugs and vaccines), [109] as well as molecular epidemiology. Our work subsequently expanded to include epidemiology, bacteriology, genetics, immunology and the various 'omics' technologies that are now well known. We have used these tools in basic research, but also for direct and individual bench-to-bedside healthcare, and also to understand the dynamics of the disease in order to best design intervention and prevention strategies. In this context, CTR research findings have highlighted incorrect assumptions, led to improved understanding and, in the process, inspired ourselves and others to contribute towards TB research in new ways. We firmly believe that the CTR's research has shaped our knowledge and helped us to avoid continuing the mistakes of the past. 
